Pinsent Masons advises the UK government on purchase of further 60m doses of Covid-19 vaccines
10 May 2021 | 09:36 am |
Multinational law firm Pinsent Masons has successfully advised the UK government on an agreement to purchase an additional 60m doses of the Pfizer BioNTech Covid-19 vaccine for the autumn revaccination programme.
The team at Pinsent Masons was led by Life Sciences transactions partner Allistair Booth and included Andy Cornforth, Niki Ruprai, Robert Sherville-Payne and Aaron Hope.
Commenting on the agreement, Allistair Booth, lead partner at Pinsent Masons said:
"This is an important agreement. Access to 60m doses of that vaccine in time for an autumn revaccination programme will hopefully play a key role in protecting the NHS and the most vulnerable people of the UK.
"We are proud to have worked with the UK government on securing this agreement for such an important vaccine at such a crucial time".
Key Contacts
Latest press releases
Show me all press releasesPinsent Masons announces new co-heads of Madrid, Inmaculada Castelló and Fernando Gutiérrez
Multinational law firm Pinsent Masons has appointed Inmaculada Castelló and Fernando Gutiérrez as co-heads of the Madrid office as of 1 September 2022.
Pinsent Masons advises UMS Consulting on its acquisition by Expleo
Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.
Pinsent Masons advises climate-tech venture capital fund, Systemiq Capital, on the $70m closing of its second fund
Multinational law firm Pinsent Masons has advised climate-tech VC fund Systemiq Capital on the $70 million first close of its second fund, targeting $200 million to continue backing the best early-stage climate tech entrepreneurs.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons advises UMS Consulting on its acquisition by Expleo
Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.
Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Pinsent Masons launches parallel trade monitoring platform for life sciences sector
Multinational law firm Pinsent Masons launches innovative online tool to help life sciences organisations grappling with parallel trade management.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]